Hospital outcomes for transcatheter aortic valve replacement (TAVR) may be dependent on the quality of evaluation, personnel, and procedural and postprocedural care common to patients undergoing cardiac surgery.
T ranscatheter aortic valve replacement (TAVR) has become a widely used alternative treatment for patients with severe aortic valve stenosis, based on clinical trials demonstrating comparable or even superior results compared with surgical aortic valve replacement (SAVR) among patients at extreme, high, and intermediate risk for surgery. [1] [2] [3] [4] [5] Current aortic valve replacement guidelines recommend a comprehensive approach toward treatment selection with periprocedural evaluation by a multidisciplinary heart team that integrates multiple parameters to select the optimal patients for each procedure. 6, 7 A heart team's composition may include a variety of groups including cardiologists, cardiac surgeons, case managers, catheterization laboratory team members, operating room staff, and advanced practice professionals. It is likely that the involvement of surgeons and surgical intensive care units may have strong effects on the evaluation, procedural care, and postprocedural management of patients undergoing TAVR procedures. Therefore, it is plausible that the quality of a hospital's surgical program may be influential in how hospitals fare when they initiate new TAVR programs.
In this study, we evaluated whether hospitals with better outcomes after SAVR also achieved better outcomes after initiating TAVR programs. Specifically, using national data among patients insured by Medicare in fee-for-service programs, we hypothesized that those hospitals with lower risk-adjusted 30-day mortality after SAVR prior to TAVR approval also achieved lower mortality rates after TAVR.
Methods

Study Population
We evaluated patients 65 years and older in the United States using the Centers for Medicare and Medicaid Services Medicare Provider and Review database. We included patients with at least 1 procedural code for SAVR (defined by International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes 35.21 or 35.22) or TAVR (ICD-9-CM codes 35.05 or 35.06), between January 1, 2010, and September 29, 2015 . 8 The Medicare Provider and Review database is a 100% sample of administrative discharge billing claims for inpatient hospitalizations for beneficiaries of Medicare fee-forservice insurance programs, and it has been used extensively for prior research on health outcomes. [9] [10] [11] Only hospitals performing at least 1 isolated SAVR (ie, SAVR without a concomitant coronary artery bypass procedure or other valvular surgery, as defined in eTable 1 in the Supplement) prior to September 1, 2011 (pre-TAVR period) , and at least 1 TAVR after this date (post-TAVR period) were included in the analysis. The study was approved by the institutional review board of Beth Israel Deaconess Medical Center, with a waiver of informed consent for retrospective data analysis.
Covariates and Outcomes
Baseline covariates were ascertained using secondary diagnosis codes that were coded as present on admission during the index hospitalization, as well as from principal and secondary diagnosis codes from all hospitalizations in the year prior to the date of admission for the index hospitalization (eTable 2 in the Supplement). Covariates were chosen based on inclusion in the Elixhauser Comorbidity Index, a validated summary measure that has previously been shown to be associated with mortality in the Medicare population. 12 To identify hospital characteristics, we used the American Hospital Association's 2012 Annual Survey Database. The primary outcome was all-cause 30-day mortality determined through linkage of the Medicare Provider and Review files to the Medicare Beneficiary Summary File, which includes vital status information. We additionally determined 1-year mortality as a secondary outcome. Time to death was calculated as the time between the date of the index procedure and the date of death.
Statistical Analysis
Hospital SAVR quality was determined based on a hospital's risk-adjusted 30-day mortality rate in the period prior to the introduction of TAVR (January 1, 2010, to September 1, 2011) . Mortality rates exclusively during the pre-TAVR period were used, because the introduction of TAVR may have influenced SAVR outcomes owing to the shifting of patients from SAVR to TAVR. 13 We created a mixed-effects logistic regression model Observed 30-day and 1-year TAVR mortality rates were determined by quartile of risk-adjusted SAVR mortality. To assess whether results were sensitive to the inclusion of lowvolume hospitals, we reran the analysis after excluding hospitals with procedure volumes less than 10. Multivariable logistic and Cox regression, accounting for clustering by hospital, were then used to determine the adjusted association between baseline
Key Points
Question Do hospitals with better patient outcomes for surgical aortic valve replacement (SAVR) subsequently achieve better transcatheter aortic valve replacement (TAVR) outcomes after launching TAVR programs?
Findings This study demonstrates that hospitals with historically lower risk-adjusted mortality rates after SAVR subsequently achieved better short and long term outcomes for TAVR as measured by 30-day and 1-year mortality.
Meaning High-quality surgical programs were likely a crucial component of successful TAVR programs, and this metric may shed light on the outcomes that hospitals developing new TAVR programs might achieve.
hospital SAVR mortality quartile and 30-day and 1-year TAVR mortality, respectively. Both models were adjusted for patient risk factors, including age, sex, Elixhauser Comorbidity Index, access site, hospital TAVR volume, and other hospital characteristics. We used the same multivariable methods to determine the adjusted association between baseline hospital SAVR mortality rates as a continuous variable and 30-day and 1-year TAVR mortality. Furthermore, we repeated the same method to analyze subgroups based on access site (ie, transfemoral vs transapical), and the results were presented in a forest plot.
Cumulative incidence curves were created to plot time to death, stratified by quartile of SAVR quality. Log-rank tests were used to compare the survival distributions of each group. All statistical analyses were performed in Stata, version 15.0 (StataCorp) from June 2018 to August 2018, using a 2-tailed P value less than .05 for significance.
Results
Overall Results
A total of 1071 hospitals performed at least 1 isolated SAVR procedures (n = 33 430) in the pre-TAVR period, of which 519 (48.5%) eventually performed at least 1 TAVR during the study period and were included in the analysis ( Figure 1 ). Of these hospitals, 370 (71.3%) were teaching hospitals and the mean (SD) number of beds was 490 (289). Hospital 30-day risk-adjusted SAVR mortality rates in the pre-TAVR period are shown in Figure 2A . The mean 30-day risk-adjusted SAVR mortality rate in the pre-TAVR period was 3.9% (range, 1.7%-8.1%). A total of 51 924 TAVR procedures were performed after September 1, 2011, in Table 1 ). Unadjusted 1-year TAVR mortality curves stratified by quartiles are presented in Figure 2B . The 1-year mortality rate was 17.5% (95% CI, 16.9%-18.1%) for hospitals in quartile 1 (reference), 18.4% (95% CI, 17.5%-19.4%) in quartile 2 (log-rank P = .20), 19.0% (95% CI, 18.3%-19.8%) in quartile 3 (log-rank P = .007), and 19.4% (95% CI, 18.7%-20.1%) in quartile 4 (log-rank P < .001). After exclusion of hospitals performing fewer than 10 TAVRs during the study period, our results were substantively unchanged (eTable 3 in the Supplement). On multivariable analysis, undergoing TAVR at a hospital with higher baseline SAVR mortality continued to be associated with higher mortality at 30 days after TAVR ( Table 2) . Compared with quartile 1, the odds ratio (OR) for quartile 2 was 1.02 (95% CI, 0.87-1.21); it was 1.13 for quartile 3 (95% CI, 1.02-1.26) and 1.23 for quartile 4 (95% CI, 1.07-1.40; P = .02 across quartiles). At 1 year, the hazard ratio for quartile 2 was 1.04 (95% CI, 0.92-1.17), while that of quartile 3 was 1.14 (95% CI, 1.02-1.28), and that of quartile 4 was 1.16 (95% CI, 1.05-1.28; P =.02 across quartiles). When modeled as a continuous variable, higher hospital SAVR mortality rates continued to be associated with higher TAVR mortality at 30 days (OR, 1.07 [95% CI, 1.03-1.11]; P < .001) and 1 year (hazard ratio, 1.034 [95% CI, 1.02-1.06]; P < .001).
In subgroup analyses stratified by transfemoral vs transapical access sites, we found that higher baseline hospital SAVR mortality rates continued to be associated with higher 30-day mortality in transfemoral procedures (ORs: quartile 2, 0. Figure 3) . The association between baseline hospital SAVR mortality and TAVR mortality was stronger for transapical TAVR at 30 days than transfemoral TAVR (interaction P = .048), but these values were not significantly different at 1 year (interaction P = .11).
Discussion
While SAVR has long been the mainstay of treatment for severe aortic valve disease, TAVR has now surpassed SAVR in both the United States and Europe as the predominant treatment for severe symptomatic aortic stenosis. [15] [16] [17] Because of the importance of cardiac surgical care and setting in the performance of TAVR, we hypothesized that the existence of higherquality surgical programs may have been associated with better outcomes on their establishment of new TAVR programs. In this study, we demonstrated that hospitals with higher riskadjusted mortality after SAVR prior to TAVR approval did indeed have higher short-term and long-term mortality for TAVR during the early phase of TAVR introduction and growth in the United States. This association between baseline SAVR quality and subsequent TAVR outcomes persisted after adjustment for hospital TAVR volume, which has a powerful association with TAVR outcomes, 18 as well as patient comorbidities and other hospital characteristics. Recent guidelines on the management of aortic valve disease have positioned the heart valve team at the center of the decision-making process for the assessment of patients with aortic valve stenosis. 6, 7 Ideally, members of the heart valve team should work in a coordinated manner to select the most beneficial treatment for each patient, manage procedural decisions, and coordinate postprocedural care. Surgical teams and units remain integral to many TAVR programs, and the most severe complications of TAVR, including aortic dissection, left ventricle perforation, and valve embolization or migration, may require emergency surgery.
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Hospitals with better SAVR quality as measured by lower risk-adjusted mortality rates may have subsequently had lower TAVR mortality for a number of reasons. First, higher-quality surgical programs may have had better patient selection, more highly functioning operating theaters (where TAVRs are commonly performed, particularly early after approval), and betterquality cardiac surgical care units. Additionally, subgroup analyses showed that patients undergoing transapical procedures in particular might have benefited from using higherquality surgical centers.
Limitations
The current study has several limitations worth noting. First, the study is retrospective and based on administrative data and is therefore subject to residual confounding owing to unmeasured variables as well as inaccuracies in coding. Highquality surgical programs may have been correlated with improved systems of care and not directly associated with better TAVR outcomes. Second, because claims data represent billing diagnoses, they may not accurately reflect the presence and severity of clinical conditions. Institutions whose patients have more complex needs, based on comorbidities not available in claims data, may have artifactually lower risk-adjusted mortality rates for SAVR, TAVR, or both. Third, because of the limited granularity in the administrative dataset, we were not able to calculate traditional surgical risk scores, such as Society for Thoracic Surgery Predicted Risk of Mortality 20 and logistic European System for Cardiac Operative Risk Evaluation.
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Another limitation is that we were not able to ascertain whether patients recovered in cardiac surgical intensive care units vs coronary care units. Finally, the observed patterns may not reflect overall patterns outside the United States and in US patients who are not Medicare beneficiaries.
Conclusions
Our findings may help inform professional societies currently updating recommendations for institutional and heart valve team requirements for TAVR. Patients, families, and referring clinicians need to make informed decisions regarding where they seek medical care, especially when that care involves a procedure with high complexity and major risks. Hospitals with higher SAVR mortality rates in the pre-TAVR period also had higher short-term and long-term TAVR mortality rates after initiating TAVR programs. The quality of cardiac surgical care may be associated with a hospital's performance with new structural heart disease programs. High-quality surgical programs were likely a critical component of successful TAVR programs, and this metric may shed light on the outcomes hospitals looking to develop new TAVR programs might achieve. There has been much recent attention to the quality of care delivered by transcatheter aortic valve replacement (TAVR) programs, including whether the experience of the team is an important determinant of quality. Experience can be expressed as the duration of a program being open and the volume of procedures the team have performed. If a clinically meaningful association between volume and outcome is redemonstrated using data from the current era of new technologies and expanding indications, then this could influence professional societies' guidelines, expert consensus documents, and government policy decisions. Specifically, the national coverage analysis for TAVR is now being performed by the Centers for Medicare and Medicaid, after they reopened the national coverage decision on June 27, 2018. 1 The Centers for Medicare and Medicaid has gathered input from a recent Medicare Evidence Development and Coverage Advisory Committee meeting and written submissions during the initial public comment period. The national coverage analysis has an expected completion date of June 25, 2019, and it could result in an updated national coverage decision that includes requirements for clinicians and sites to qualify for coverage of TAVR. 1 The recently published professional society document 2 does recommend a surgical aortic valve replacement (SAVR) volume threshold and a recommendation that TAVR sites must achieve an acceptable SAVR outcomes metric.
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